ΜΟΡΙΑ- ΠΙΘΑΝΟΙ ΘΕΡΑΠΕΥΤΙΚΟΙ ΣΤΟΧΟΙ ΤΟΥ HIV Κωστούλα Ευγενία-Αγγελική Εφραιμίδης Ιάσονας
Στόχοι για την αναστολή του κύκλου ζωής του ιού με φαρμακολογικούς παράγοντες Τρόπος Δράσης Έγκριση FDA Reverse Transcriptase Inhibitors (RTIs) Nucleoside/Nucleotide Analogues (NRTIs) Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) 1987 1996 Protease Inhibitors (PIs) 1995 Fixed-Dose Combination Antiretrovirals Fusion Inhibitors 2003 Chemokine Coreceptor Antagonists 2007 Integrase Inhibitors Maturation Inhibitors
HIV-1 uses dynamic capsid pores to import nucleotides and fuel encapsidated DNA synthesis. August, 2016 (Nature) Scientists from UCL and Cambridge Hexameric Hiv-1 CA in Complex With Hexacarboxybenzene Jacques DA, McEwan WA. Nature, 2016
Ibalizumab monoclonal antibody looks promising for people with drug-resistant HIV November, 2016 (IDWeek 2016, New Orleans) US FDA (to be approved in 2016) First biologic drug for HIV Lalezari J et al. Primary efficacy endpoint and safety results of ibalizumab (IBA) in a phase 3 study of heavily treatment-experienced patients with multi-drug resistant (MDR) HIV-1 infection. IDWeek, New Orleans, abstract LB-6, 2016.
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy HAART (Highly Active Antiretroviral Therapy) November, 2014- October, 2016 50 patients, 5 UK Universities Julian H. Elliott , Fiona Wightman. November, 2014. Sarah Fidler, Imperial College, London. October, 2016.
Ευχαριστούμε για την προσοχή σας